Credit Suisse Group AG reiterated their buy rating on shares of Prothena Corp. (NASDAQ:PRTA) in a research report sent to investors on Tuesday morning. Credit Suisse Group AG currently has a $65.00 price objective on the stock.
Several other research firms have also recently weighed in on PRTA. Wedbush reaffirmed an outperform rating and set a $77.00 price objective on shares of Prothena Corp. in a research report on Monday. Barclays PLC upped their target price on Prothena Corp. from $60.00 to $70.00 and gave the stock an overweight rating in a report on Thursday, August 4th. Finally, Royal Bank Of Canada reiterated an outperform rating and set a $95.00 target price on shares of Prothena Corp. in a report on Monday, July 18th. One research analyst has rated the stock with a hold rating and five have issued a buy rating to the company’s stock. Prothena Corp. presently has a consensus rating of Buy and an average target price of $76.80.
Prothena Corp. (NASDAQ:PRTA) opened at 58.14 on Tuesday. Prothena Corp. has a 52 week low of $28.20 and a 52 week high of $76.42. The company’s market cap is $2.00 billion. The company’s 50-day moving average price is $55.88 and its 200 day moving average price is $47.62.
Prothena Corp. (NASDAQ:PRTA) last posted its quarterly earnings data on Tuesday, August 2nd. The company reported ($1.18) earnings per share for the quarter, missing the consensus estimate of ($0.91) by $0.27. The firm had revenue of $0.33 million for the quarter, compared to analyst estimates of $0.39 million. Prothena Corp. had a negative return on equity of 28.15% and a negative net margin of 8,628.11%. The firm’s quarterly revenue was up 22.2% compared to the same quarter last year. On average, analysts anticipate that Prothena Corp. will post ($4.25) EPS for the current year.
In other Prothena Corp. news, insider Arthur W. Homan sold 9,375 shares of the company’s stock in a transaction that occurred on Wednesday, July 20th. The stock was sold at an average price of $52.14, for a total value of $488,812.50. Following the sale, the insider now owns 9,375 shares in the company, valued at $488,812.50. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, insider Karin L. Walker sold 12,000 shares of the company’s stock in a transaction that occurred on Monday, September 19th. The shares were sold at an average price of $61.10, for a total value of $733,200.00. Following the completion of the sale, the insider now owns 7,000 shares in the company, valued at approximately $427,700. The disclosure for this sale can be found here. Corporate insiders own 3.70% of the company’s stock.
Hedge funds have recently added to or reduced their stakes in the stock. BlackRock Inc. raised its stake in Prothena Corp. by 197.8% in the first quarter. BlackRock Inc. now owns 2,656 shares of the company’s stock valued at $110,000 after buying an additional 1,764 shares in the last quarter. Societe Generale acquired a new stake in Prothena Corp. during the second quarter valued at about $111,000. Amalgamated Bank acquired a new stake in Prothena Corp. during the second quarter valued at about $208,000. Teacher Retirement System of Texas raised its stake in Prothena Corp. by 14.0% in the second quarter. Teacher Retirement System of Texas now owns 4,021 shares of the company’s stock valued at $141,000 after buying an additional 493 shares in the last quarter. Finally, BNP Paribas Arbitrage SA raised its stake in Prothena Corp. by 49.9% in the second quarter. BNP Paribas Arbitrage SA now owns 4,039 shares of the company’s stock valued at $141,000 after buying an additional 1,344 shares in the last quarter.
Prothena Corp. Company Profile
Prothena Corporation Public Limited Company is a global biotechnology company. The Company is focused on the discovery, development and commercialization of immunotherapies for the treatment of diseases that involve protein misfolding or cell adhesion. The Company’s clinical pipeline of antibody-based product candidates targets a range of indications, including Amyloid Light-chain (AL) amyloidosis (NEOD001), Parkinson’s disease and other related synucleinopathies (PRX002), and inflammatory diseases, including psoriasis (PRX003).
Receive News & Ratings for Prothena Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Prothena Corp. and related companies with MarketBeat.com's FREE daily email newsletter.